生物工程蛋白質與酵素市場：策略性洞察與預測（2026-2031年）

生物工程蛋白質和酵素市場預計將以 10.8% 的複合年成長率成長，從 2026 年的 69 億美元成長到 2031 年的 115 億美元。

全球生物工程蛋白和酵素市場是現代生物技術的核心，其發展得益於合成生物學、重組DNA技術和精準生物製造的快速進步。這些工程化生物分子正日益廣泛地應用於製藥、工業流程、農業和食品生產等領域。市場受益於對生物製藥、標靶治療和永續工業解決方案日益成長的需求。同時，人工智慧和基因編輯技術的融合正在加速蛋白質設計和生產的效率提升。隨著各行業轉向高性能、環境友善的傳統化學品替代品，生物工程蛋白和酵素正成為下一代製造和醫療保健系統的關鍵組成部分。

市場促進因素

推動這一趨勢的主要動力之一是對先進生物製藥和標靶治療日益成長的需求。癌症、自體免疫疾病和代謝紊亂等慢性疾病的日益普遍，促使人們採用工程化蛋白質，例如單株抗體、細胞激素和治療性酵素。與傳統治療方法相比，這些生物分子具有更高的特異性和更佳的臨床療效。

蛋白質工程和合成生物學領域的技術進步正在進一步加速市場成長。 CRISPR基因編輯、人工智慧驅動的蛋白質建模和定向進化等創新技術，使得開發具有更高穩定性和功能性的客製化蛋白質成為可能。

工業生物技術的應用範圍不斷擴大，也顯著推動了市場成長。由於其高效能、​​低能耗和環境優勢，工程酵素正日益取代食品加工、清潔劑、生質燃料和農業等產業中的化學催化劑。此外，人們對永續性和綠色化學的日益關注，也推動了各行業採用酶法工藝，從而減少廢棄物和排放。

市場限制因素

該市場面臨研發成本高昂的限制因素。開發生物工程蛋白質和酵素需要先進的實驗室設備、熟練的專業人員和複雜的生物製程基礎設施，這導致巨額資本投入和漫長的研發週期。

監管的複雜性也是一項重大挑戰，尤其對於治療性蛋白質。嚴格的核准流程、大規模臨床試驗和生物安全要求都會延長產品上市時間並增加合規成本。

生產規模化仍然是一個令人擔憂的問題。大規模生產穩定、高品質的蛋白質面臨許多技術挑戰，例如產量最佳化、污染控制和批次間差異等，這些都會影響商業化效率。

對技術和細分市場的洞察

市場細分按產品類型、應用和生產技術進行。重組蛋白佔據主要市場佔有率，這主要得益於其在治療和研究領域的廣泛應用。這包括用於治療複雜疾病的單株抗體、荷爾蒙和細胞激素。

從應用領域來看，生物製藥產業是市場的主要驅動力，這主要得益於藥物研發、生物製藥生產和精準醫療領域的大量投資。工業應用也在迅速擴展，工程酶提高了製程效率和永續性，尤其是在食品加工、生質燃料和紡織業。

從技術角度來看，微生物表現系統、哺乳動物細胞培養和新興的無細胞合成系統等平台正在推動創新。人工智慧驅動的蛋白質設計和高通量篩檢進一步提高了研發速度和產品性能。

競爭格局與策略展望

全球生技和化學企業專注於創新和產品組合拓展，其競爭格局呈現出顯著特徵。賽默飛世爾科技、默克集團、百奧泰克公司、金斯瑞生物科技和BASF等主要企業正在投資先進的蛋白質工程平台，並擴大其生物製造能力。

策略性措施包括與研究機構建立合作關係、開發人工智慧驅動的蛋白質設計工具，以及拓展個人化醫療和工業生物技術等高成長領域。此外，各公司正致力於研發可擴展的生產技術，以滿足日益成長的全球需求。

結論

受技術進步、生物製藥需求成長和工業應用拓展的推動，全球生物工程蛋白質和酵素市場預計將呈現強勁成長。儘管高成本、監管障礙和規模化生產的挑戰仍然存在，但合成生物學和生物製造領域的持續創新將推動市場長期擴張。

本報告的主要益處

• 深入分析：獲得跨地區、客戶群、政策、社會經濟因素、消費者偏好和產業領域的詳細市場洞察。
• 競爭格局：了解主要企業的策略趨勢，並確定最佳的市場進入方式。
• 市場促進因素與未來趨勢：我們評估影響市場的關鍵成長要素和新興趨勢。
• 實用建議：我們支援制定策略決策以開發新的收入來源。
• 適合各類讀者：非常適合Start-Ups、研究機構、顧問公司、中小企業和大型企業。

我們的報告的使用範例

產業和市場洞察、機會評估、產品需求預測、打入市場策略、區域擴張、資本投資決策、監管分析、新產品開發和競爭情報。

報告範圍

• 2021年至2025年的歷史數據和2026年至2031年的預測數據
• 成長機會、挑戰、供應鏈前景、法律規範與趨勢分析
• 評估競爭對手的市場定位、策略和市場佔有率。
• 細分市場和區域銷售成長及預測評估
• 公司簡介，包括策略、產品、財務狀況和主要發展動態。

目錄

第1章執行摘要

第2章：市場概述

• 市場概覽
• 市場的定義
• 調查範圍
• 市場區隔

第3章：商業環境

• 市場促進因素
• 市場限制因素
• 市場機遇
• 波特五力分析
• 產業價值鏈分析
• 政策與法規
• 策略建議
• 產品平臺分析
• 發病率和盛行率分析
• 專利分析

第4章 技術展望

第5章：生物工程蛋白質與酵素市場：依產品類型分類

• 重組蛋白
• 治療性蛋白質
• 工業酵素
• 診斷酶
• 特殊蛋白質
• 生物相似藥

第6章：生物工程蛋白質與酵素市場：依應用領域分類

• 生物製藥
• 診斷和檢查
• 食品/飲料
• 飼料和營養
• 生質燃料和能源
• 清潔劑和織物
• 農業/作物保護
• 化妝品和個人護理
• 環境生物技術

第7章：生物工程蛋白質與酵素市場：依最終使用者分類

• 製藥和生物技術公司
• 合約研究組織/合約開發組織（CRO/CDMO）
• 學術和研究機構
• 工業製造商
• 食品和飲料製造商
• 農業和畜牧公司

第8章：生物工程蛋白質與酵素市場：按地區分類

• 北美洲
  • 美國
  • 加拿大
  • 墨西哥
• 南美洲
  • 巴西
  • 阿根廷
  • 其他
• 歐洲
  • 英國
  • 德國
  • 法國
  • 西班牙
  • 其他
• 中東和非洲
  • 沙烏地阿拉伯
  • UAE
  • 其他
• 亞太地區
  • 中國
  • 印度
  • 日本
  • 韓國
  • 印尼
  • 泰國
  • 其他

第9章：競爭環境與分析

• 主要企業及策略分析
• 市佔率分析
• 合併、收購、協議和合作關係
• 競爭環境儀錶板

第10章：公司簡介

• Thermo Fisher Scientific Inc.
• Merck KGaA
• Bio-Techne Corporation
• Abcam plc
• GenScript Biotech Corporation
• Sino Biological Inc.
• Novonesis
• Codexis, Inc.
• BASF SE
• Advanced Enzyme Technologies Ltd.

第11章附錄

The Bioengineered Proteins and Enzymes market is expected to grow at a CAGR of 10.8%, reaching USD 11.5 billion in 2031 from USD 6.9 billion in 2026.

The global bioengineered proteins and enzymes market is positioned at the core of modern biotechnology, driven by rapid advancements in synthetic biology, recombinant DNA technology, and precision biomanufacturing. These engineered biomolecules are increasingly used across pharmaceuticals, industrial processing, agriculture, and food production. The market is benefiting from the growing demand for biologics, targeted therapies, and sustainable industrial solutions. In parallel, the integration of artificial intelligence and gene editing technologies is accelerating protein design and production efficiency. As industries shift toward high-performance, eco-friendly alternatives to conventional chemicals, bioengineered proteins and enzymes are becoming critical components of next-generation manufacturing and healthcare systems.

Market Drivers

A major driver is the rising demand for advanced biologics and targeted therapies. Increasing prevalence of chronic diseases such as cancer, autoimmune disorders, and metabolic conditions is driving the adoption of engineered proteins including monoclonal antibodies, cytokines, and therapeutic enzymes. These biomolecules offer higher specificity and improved clinical outcomes compared to traditional treatments.

Technological advancements in protein engineering and synthetic biology are further accelerating market growth. Innovations such as CRISPR gene editing, AI-based protein modeling, and directed evolution techniques are enabling faster and more precise development of customized proteins with enhanced stability and functionality.

The expansion of industrial biotechnology applications also contributes significantly. Engineered enzymes are increasingly replacing chemical catalysts in industries such as food processing, detergents, biofuels, and agriculture due to their efficiency, lower energy requirements, and environmental benefits. Additionally, growing emphasis on sustainability and green chemistry is encouraging industries to adopt enzyme-based processes that reduce waste and emissions.

Market Restraints

The market faces constraints related to high research and development costs. Developing bioengineered proteins and enzymes requires advanced laboratories, skilled personnel, and complex bioprocessing infrastructure, leading to significant capital investment and long development timelines.

Regulatory complexity is another key challenge, particularly for therapeutic proteins. Stringent approval processes, extensive clinical trials, and biosafety requirements increase time-to-market and compliance costs.

Manufacturing scalability also remains a concern. Large-scale production of consistent, high-quality proteins involves technical challenges such as yield optimization, contamination control, and batch variability, which can impact commercialization efficiency.

Technology and Segment Insights

The market is segmented by product type, application, and production technology. Recombinant proteins represent a dominant segment, driven by their widespread use in therapeutics and research applications. These include monoclonal antibodies, hormones, and cytokines used in treating complex diseases.

By application, the biopharmaceutical sector leads the market due to high investment in drug discovery, biologics manufacturing, and precision medicine. Industrial applications are also expanding rapidly, particularly in food processing, biofuels, and textiles, where engineered enzymes improve process efficiency and sustainability.

Technologically, platforms such as microbial expression systems, mammalian cell cultures, and emerging cell-free synthesis systems are driving innovation. AI-assisted protein design and high-throughput screening are further enhancing development speed and product performance.

Competitive and Strategic Outlook

The competitive landscape is characterized by the presence of global biotechnology and chemical companies focusing on innovation and portfolio expansion. Key players such as Thermo Fisher Scientific, Merck KGaA, Bio-Techne Corporation, GenScript Biotech, and BASF are investing in advanced protein engineering platforms and expanding their biomanufacturing capabilities.

Strategic initiatives include partnerships with research institutions, development of AI-driven protein design tools, and expansion into high-growth application areas such as personalized medicine and industrial biotechnology. Companies are also focusing on scalable production technologies to address growing global demand.

Conclusion

The global bioengineered proteins and enzymes market is expected to witness robust growth, supported by technological advancements, increasing demand for biologics, and expanding industrial applications. While high costs, regulatory hurdles, and scalability challenges remain, continuous innovation in synthetic biology and biomanufacturing will drive long-term market expansion.

Key Benefits of this Report

• Insightful Analysis: Gain detailed market insights across regions, customer segments, policies, socio-economic factors, consumer preferences, and industry verticals.
• Competitive Landscape: Understand strategic moves by key players to identify optimal market entry approaches.
• Market Drivers and Future Trends: Assess major growth forces and emerging developments shaping the market.
• Actionable Recommendations: Support strategic decisions to unlock new revenue streams.
• Caters to a Wide Audience: Suitable for startups, research institutions, consultants, SMEs, and large enterprises.

What Businesses Use Our Reports For

Industry and market insights, opportunity assessment, product demand forecasting, market entry strategy, geographical expansion, capital investment decisions, regulatory analysis, new product development, and competitive intelligence.

Report Coverage

• Historical data from 2021 to 2025 and forecast data from 2026 to 2031
• Growth opportunities, challenges, supply chain outlook, regulatory framework, and trend analysis
• Competitive positioning, strategies, and market share evaluation
• Revenue growth and forecast assessment across segments and regions
• Company profiling including strategies, products, financials, and key developments

TABLE OF CONTENTS

1. EXECUTIVE SUMMARY

2. MARKET SNAPSHOT

• 2.1. Market Overview
• 2.2. Market Definition
• 2.3. Scope of the Study
• 2.4. Market Segmentation

3. BUSINESS LANDSCAPE

• 3.1. Market Drivers
• 3.2. Market Restraints
• 3.3. Market Opportunities
• 3.4. Porter's Five Forces Analysis
• 3.5. Industry Value Chain Analysis
• 3.6. Policies and Regulations
• 3.7. Strategic Recommendations
• 3.8. Product Pipeline Analysis
• 3.9. Incidence and Prevalence Analysis
• 3.10. Patent Analysis

4. TECHNOLOGICAL OUTLOOK

5. BIOENGINEERED PROTEINS AND ENZYMES MARKET BY PRODUCT TYPE

• 5.1. Introduction
• 5.2. Recombinant Proteins
• 5.3. Therapeutic Proteins
• 5.4. Industrial Enzymes
• 5.5. Diagnostic Enzymes
• 5.6. Specialty Proteins
• 5.7. Biosimilars

6. BIOENGINEERED PROTEINS AND ENZYMES MARKET BY APPLICATION

• 6.1. Introduction
• 6.2. Biopharmaceuticals
• 6.3. Diagnostics & Research
• 6.4. Food & Beverages
• 6.5. Animal Feed & Nutrition
• 6.6. Biofuels & Energy
• 6.7. Detergents & Textiles
• 6.8. Agriculture & Crop Protection
• 6.9. Cosmetics & Personal Care
• 6.10. Environmental Biotechnology

7. BIOENGINEERED PROTEINS AND ENZYMES MARKET BY END-USER

• 7.1. Introduction
• 7.2. Pharmaceutical & Biotechnology Companies
• 7.3. Contract Research and Manufacturing Organizations (CROs/CDMOs)
• 7.4. Academic and Research Institutions
• 7.5. Industrial Manufacturers
• 7.6. Food & Beverage Manufacturers
• 7.7. Agriculture & Livestock Firms

8. BIOENGINEERED PROTEINS AND ENZYMES MARKET BY GEOGRAPHY

• 8.1. Introduction
• 8.2. North America
  • 8.2.1. USA
  • 8.2.2. Canada
  • 8.2.3. Mexico
• 8.3. South America
  • 8.3.1. Brazil
  • 8.3.2. Argentina
  • 8.3.3. Others
• 8.4. Europe
  • 8.4.1. United Kingdom
  • 8.4.2. Germany
  • 8.4.3. France
  • 8.4.4. Spain
  • 8.4.5. Others
• 8.5. Middle East and Africa
  • 8.5.1. Saudi Arabia
  • 8.5.2. UAE
  • 8.5.3. Others
• 8.6. Asia Pacific
  • 8.6.1. China
  • 8.6.2. India
  • 8.6.3. Japan
  • 8.6.4. South Korea
  • 8.6.5. Indonesia
  • 8.6.6. Thailand
  • 8.6.7. Others

9. COMPETITIVE ENVIRONMENT AND ANALYSIS

• 9.1. Major Players and Strategy Analysis
• 9.2. Market Share Analysis
• 9.3. Mergers, Acquisitions, Agreements, and Collaborations
• 9.4. Competitive Dashboard

10. COMPANY PROFILES

• 10.1. Thermo Fisher Scientific Inc.
• 10.2. Merck KGaA
• 10.3. Bio-Techne Corporation
• 10.4. Abcam plc
• 10.5. GenScript Biotech Corporation
• 10.6. Sino Biological Inc.
• 10.7. Novonesis
• 10.8. Codexis, Inc.
• 10.9. BASF SE
• 10.10. Advanced Enzyme Technologies Ltd.

11. APPENDIX

• 11.1. Currency
• 11.2. Assumptions
• 11.3. Base and Forecast Years Timeline
• 11.4. Key benefits for the stakeholders
• 11.5. Research Methodology
• 11.6. Abbreviations